SHEET 005 — Q&A
Retatrutide: 22 questions answered directly.
Common questions about retatrutide's approval status, mechanism, safety, kidney data, and how it compares with tirzepatide — answered plainly from the published record.
Does retatrutide cause bone fractures or affect kidney function at higher doses?
Bone fracture data from Phase 2 trials have not been specifically highlighted as a safety signal. For kidney function, Phase 2 substudy data published in 2025 showed favorable kidney signals: UACR (urine albumin-to-creatinine ratio, a marker of kidney health) fell approximately 37% in type 2 diabetes participants and 28–31% in obesity participants at higher doses, versus placebo [11]. Estimated glomerular filtration rate (eGFR — kidney filtration efficiency) improved in the obesity group [11]. Long-term kidney data are being studied in the ongoing TRANSCEND-CKD Phase 3 trial [12].
Is retatrutide safe for people with kidney disease?
Dedicated kidney-disease data are emerging but not complete. The 2025 Kidney International Reports substudy showed reductions in UACR and improvements in eGFR at higher doses in both obesity and type 2 diabetes groups [11]. A 2025 systematic review and meta-analysis in Maedica found significant glycemic and weight reduction in CKD comorbid patients, with lower doses (8 mg or below) showing greater HbA1c benefit, and a renoprotective signal via albuminuria reduction [14]. The TRANSCEND-CKD Phase 3 trial is specifically evaluating retatrutide in people with CKD [12]. Complete safety data for people with kidney disease are pending.
What cardiovascular and kidney outcomes is retatrutide being evaluated for in Phase 3?
NCT06383390 is the dedicated Phase 3 outcomes trial evaluating retatrutide's effects on cardiovascular events and kidney function parameters [7]. The TRANSCEND-CKD trial (NCT05929066 — see the design paper in Nephrology Dialysis Transplantation, 2025) is the Phase 3 trial specifically in chronic kidney disease [12]. The 2026 review of retatrutide in cardiovascular-kidney-metabolic (CKM) syndrome, published in Cardiology in Review, reports 8.79 mmHg systolic blood pressure reduction and 24.2% total body weight loss at 48 weeks from Phase 2 data, with significant attenuation of urine albumin-to-creatinine ratio [13]. Phase 3 results are not yet available.
What does retatrutide do?
Retatrutide activates three hormone receptors simultaneously — GIP, GLP-1, and glucagon receptors. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation improves insulin secretion after eating and has effects on fat tissue. Glucagon receptor activation increases energy expenditure and promotes hepatic (liver) fat breakdown. The combined effect in Phase 2 trials: mean body-weight reduction of up to -24.2% at 48 weeks in obesity [1], HbA1c reduction of 2.02% in type 2 diabetes [2], and liver-fat reduction of -82.4% in MASLD [5]. A 2025 review characterizes this triple-agonist pharmacology as a step-change in the obesity drug landscape [6].
How does retatrutide work?
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone. It simultaneously engages three class-B GPCRs (G-protein-coupled receptors — cell-surface proteins that relay hormone signals into cells): the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Cryo-EM structural studies mapped its binding at atomic resolution [3]. The GLP-1 and GIP arms reduce appetite and improve insulin secretion. The glucagon arm adds energy expenditure and hepatic lipid mobilization — mechanisms absent in GLP-1 single-agonists. The full mechanistic walkthrough is at how does retatrutide work.
How to reconstitute retatrutide?
Retatrutide has no approved formulation for non-trial use. In clinical trials it was administered by study personnel as a subcutaneous injection — not reconstituted from lyophilized (freeze-dried) powder by participants. No reconstitution protocol appears in any published Phase 1 or Phase 2 paper. Providing reconstitution instructions for gray-market material of unverified identity and purity is outside the scope of this site.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any regulatory agency as of mid-2026. It is an investigational new drug in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. A 2025 systematic review identified retatrutide as one of 14 agents with ongoing Phase 3 obesity trials [9]. Regulatory review and potential approval would follow Phase 3 completion — a process that has not yet concluded.
When will retatrutide be available?
No regulatory approval date has been announced as of mid-2026. The TRIUMPH Phase 3 program began enrolling in 2023–2024. Phase 3 obesity trials typically take 2–3 years of treatment before data lock and regulatory submission. The 2025 systematic review of emerging obesity pharmacotherapies confirmed retatrutide among 14 agents in active Phase 3 development [9], characterizing long-term cardio-renal-metabolic outcomes as the key remaining evidence gap.
How to take retatrutide?
In clinical trials, retatrutide was administered as a once-weekly subcutaneous injection by trained clinical-trial personnel, using doses stepped up gradually over several weeks to reduce GI adverse events [1][4]. Retatrutide is not available as a prescription outside clinical trials. This site does not give administration instructions for non-trial use.
How long does retatrutide take to work?
In Phase 2 obesity trials, weight loss was measurable within the first weeks of dosing and continued through week 48 without appearing to plateau at that timepoint [1]. A 2025 review of retatrutide's Phase 1/2 data notes that the weight-loss trajectory was progressive and ongoing across the 48-week period — meaning the trials ended before the maximum effect had been reached [6]. Early Phase 1b data showed -8.96 kg placebo-adjusted weight loss over just 12 weeks at the highest dose [4].
Is retatrutide better than tirzepatide?
A direct head-to-head Phase 3 trial comparing retatrutide and tirzepatide is underway but has not reported results. Without that data, direct comparison is not possible from the published record. Indirect comparison of Phase 2 figures — retatrutide at -24.2% body weight at 48 weeks [1] versus tirzepatide Phase 3 figures in a different population and protocol — is methodologically unreliable. The TRIUMPH program includes an active-comparator arm against tirzepatide; results will provide the first controlled comparative evidence.
How much retatrutide per week?
Phase 2 obesity trials studied doses of 1, 4, 8, and 12 mg once weekly by subcutaneous injection [1]. The Phase 1b trial studied 0.5–12 mg stepwise escalation [4]. There is no approved dose. Reporting these as study-design facts is appropriate; using them as personal dosing guidance is not what this page does.
How to mix retatrutide with bacteriostatic water?
Mixing retatrutide with bacteriostatic water is a step in preparing lyophilized peptide research material — a gray-market preparation process that this site does not document. No published Phase 1 or Phase 2 trial describes participant self-preparation of retatrutide. In clinical trials the compound was administered ready-prepared by study staff. Instructions for reconstituting unverified research-labeled material are not provided here.
How to switch from tirzepatide to retatrutide?
Retatrutide is not available as a prescription, so a supervised switch from tirzepatide is not currently possible outside of a clinical trial. No published trial data describe a tirzepatide-to-retatrutide transition protocol. Any comparison of agents with overlapping mechanisms (both target GIP and GLP-1 receptors) would require medical oversight for monitoring of GI effects and glucose levels.
Is retatrutide a GLP-3?
No — and the term is a misnomer. There is no GLP-3 receptor. Retatrutide is a triple agonist at three distinct receptors: GIP receptor, GLP-1 receptor, and glucagon receptor. It is accurately described as a GIP/GLP-1/glucagon tri-agonist, or simply a triple agonist. The "GLP-3" label appears in popular media and community discussions but has no pharmacological basis. Cryo-EM structural studies have confirmed its simultaneous engagement of all three receptors [3].
Is retatrutide available?
Retatrutide is not available as an approved prescription drug. It is only accessible through enrollment in an active clinical trial. Gray-market research-labeled material exists but is unregulated, of unverified identity and purity, and the FDA has issued warning letters to vendors. The 2025 systematic review of obesity pharmacotherapies confirmed retatrutide in active Phase 3 development but not approved [9].
What is retatrutide used for?
In published clinical trials, retatrutide has been studied for: obesity (primary indication — 48-week Phase 2 showing -24.2% weight loss at 12 mg) [1], type 2 diabetes (Phase 2 showing HbA1c reduction of 2.02% at 12 mg) [2], MASLD or metabolic fatty liver disease (Phase 2a showing -82.4% liver fat reduction at 24 weeks) [5], and kidney disease outcomes (ongoing Phase 3 TRANSCEND-CKD trial) [12]. A 2025 review of multifunctional incretin peptides notes emerging evidence the class could benefit fatty liver, inflammation, sleep apnea, bone health, and cognition, with retatrutide named among the agents in development [8].
What receptors does retatrutide target?
Retatrutide targets three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). All three are class-B G-protein-coupled receptors — membrane proteins that relay hormone signals into cells via a G-protein second-messenger cascade. Cryo-EM structural studies resolved the triple-agonist binding at 2.68–3.26 Å resolution and confirmed simultaneous engagement of all three receptors by the single molecule [3].
Is retatrutide legal?
Retatrutide is an investigational new drug. It is legal for Eli Lilly to develop and study it in clinical trials under IND authorization. For members of the public, retatrutide is not an approved drug and there is no legal prescription pathway. Research-labeled gray-market material occupies a regulatory gray zone: the FDA has issued warning letters for its sale, citing Federal Food, Drug, and Cosmetic Act violations. Athletes should note that GLP-1/GIP/glucagon agonists are not specifically named on the current WADA Prohibited List, but the status of investigational agents can change and should be verified against the current list.
How often do you take retatrutide?
In all published Phase 1 and Phase 2 trials, retatrutide was administered once weekly by subcutaneous injection [1][2][4]. The approximately 6-day half-life supports weekly dosing intervals, maintaining stable blood concentrations between doses [4]. No daily or biweekly dosing protocols have been published.
What is the half-life of retatrutide?
Retatrutide has an approximately 6-day half-life in human plasma, established in the Phase 1b pharmacokinetic analysis published in The Lancet in 2022 [4]. This extended half-life — achieved through a C20 fatty-diacid modification that binds the molecule to albumin — supports once-weekly subcutaneous dosing. The highest-dose group in that Phase 1b trial lost -8.96 kg (placebo-adjusted) over 12 weeks [4].
How to store retatrutide?
In clinical trials, retatrutide was handled under clinical-grade storage conditions by study sites. No approved storage protocol for any non-trial preparation exists. Gray-market research-labeled peptides are typically sold as lyophilized (freeze-dried) material requiring refrigeration, but without verified identity, purity, or stability data for the specific preparation being purchased. This site does not provide storage guidance for non-trial material.